Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Minerva Gastroenterologica e Dietologica 2019 March;65(1) > Minerva Gastroenterologica e Dietologica 2019 March;65(1):42-52

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   

Minerva Gastroenterologica e Dietologica 2019 March;65(1):42-52

DOI: 10.23736/S1121-421X.18.02525-4

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Diverticulosis today

Walter ELISEI 1, Giovanni BRANDIMARTE 2, Antonio TURSI 3

1 Division of Gastroenterology, ASL Roma 6, Albano Laziale, Rome, Italy; 2 Division of Internal Medicine and Gastroenterology, Cristo Re Hospital, Rome, Italy; 3 Service of Gastroenterology, ASL BAT, Andria, Italy



The incidence of diverticulosis and diverticular disease of the colon is increasing worldwide. Although the majority of patients remains asymptomatic long-life, the prevalence of diverticular disease of the colon, including acute diverticulitis, is substantial and is becoming a significant burden on National Health Systems in terms of direct and indirect costs. Fiber, non-absorbable antibiotics and probiotics seem to be effective in treating symptomatic and uncomplicated patients, and 5-aminosalicylic acid might help prevent acute diverticulitis. Unfortunately, robust evidence on the effectiveness of a medical strategy to prevent acute diverticulitis recurrence is still lacking. Focus is now being drawn on identifying a new endoscopic classification of the disease to evaluate the correct therapeutic approach by testing various treatments.


KEY WORDS: Diverticular diseases - Colonic diverticulosis - Mesalamine - Colonic diverticulitis - Probiotics

inizio pagina